{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:06:18Z","timestamp":1762430778966},"reference-count":39,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"abstract":"Context:<\/jats:title>Thyroglobulin (Tg) levels measured at the time of remnant ablation after thyroid hormone withdrawal (THW) were shown to have prognostic value in predicting disease-free status.<\/jats:p><\/jats:sec>Objectives:<\/jats:title>Our objectives were to determine whether stimulated Tg levels, measured at the time of remnant ablation performed under recombinant human TSH (rhTSH) stimulation, has value in predicting absence of detectable disease 1 year after radioiodine therapy and to compare the results obtained with this approach with a cohort of patients submitted to ablation after THW.<\/jats:p><\/jats:sec>Design:<\/jats:title>This was a prospective observational study.<\/jats:p><\/jats:sec>Setting and Patients:<\/jats:title>The study included 293 consecutive patients treated for a differentiated thyroid carcinoma with no initial evidence of distant metastasis. All patients were submitted to a total or near-total thyroidectomy, followed by ablation either under rhTSH (n = 151) or endogenous TSH stimulation (n = 142). Patients with positive Tg antibodies were excluded.<\/jats:p><\/jats:sec>Main Outcome Measures:<\/jats:title>The predictive value of Tg at ablation was assessed by receiver operating characteristic curve analysis.<\/jats:p><\/jats:sec>Results:<\/jats:title>In the rhTSH group, 96 patients (73.3%) were considered disease-free at 1 year. Stimulated Tg at ablation after rhTSH was found to be an independent prognostic indicator of disease persistence 12 months later. The highest-accuracy cutoff value for absence of detectable disease was defined as 7.2 ng\/mL, with a negative predictive value of 90%. In the THW group, Tg at ablation also proved to have independent predictive value. Using the same threshold (7.2 ng\/mL), the negative predictive value of Tg was 95% in the THW group.<\/jats:p><\/jats:sec>Conclusions:<\/jats:title>When rhTSH was used, stimulated Tg at ablation had independent predictive value for disease-free status 1 year later. A low stimulated Tg at rhTSH-aided ablation may be considered a favorable prognosis factor.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jc.2013-2267","type":"journal-article","created":{"date-parts":[[2013,9,14]],"date-time":"2013-09-14T04:07:52Z","timestamp":1379131672000},"page":"4364-4372","source":"Crossref","is-referenced-by-count":36,"title":["Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later"],"prefix":"10.1210","volume":"98","author":[{"given":"Miguel","family":"Melo","sequence":"first","affiliation":[{"name":"Departments of Endocrinology, Diabetes, and Metabolism (M.M., C.R., F.C., M.C.), 3000-075 Coimbra, Portugal"},{"name":"Medical Faculty (M.M., M.C.), University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (M.M., A.G.d.R., M.S.-S., P.S.) 4200-465 Porto, Portugal"}]},{"given":"Gracinda","family":"Costa","sequence":"additional","affiliation":[{"name":"Nuclear Medicine (G.C.), 3000-075 Coimbra, Portugal"}]},{"given":"Cristina","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Diabetes, and Metabolism (M.M., C.R., F.C., M.C.), 3000-075 Coimbra, Portugal"}]},{"given":"Francisco","family":"Carrilho","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Diabetes, and Metabolism (M.M., C.R., F.C., M.C.), 3000-075 Coimbra, Portugal"}]},{"given":"Maria Jo\u00e3o","family":"Martins","sequence":"additional","affiliation":[{"name":"Pathology (M.J.M.), University and Hospital Center of Coimbra, 3000-075 Coimbra, Portugal"}]},{"given":"Adriana Gaspar","family":"da Rocha","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (M.M., A.G.d.R., M.S.-S., P.S.) 4200-465 Porto, Portugal"}]},{"given":"Manuel","family":"Sobrinho-Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (M.M., A.G.d.R., M.S.-S., P.S.) 4200-465 Porto, Portugal"},{"name":"Department of Pathology and Oncology (M.S.-S., P.S.), Medical Faculty, University of Porto, 4485-661 Porto, Portugal"},{"name":"Department of Pathology (M.S.-S.), Hospital Center S. Jo\u00e3o, 4200-450 Porto, Portugal"}]},{"given":"Manuela","family":"Carvalheiro","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Diabetes, and Metabolism (M.M., C.R., F.C., M.C.), 3000-075 Coimbra, Portugal"},{"name":"Medical Faculty (M.M., M.C.), University of Coimbra, 3000-548 Coimbra, Portugal"}]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (M.M., A.G.d.R., M.S.-S., P.S.) 4200-465 Porto, Portugal"},{"name":"Department of Pathology and Oncology (M.S.-S., P.S.), Medical Faculty, University of Porto, 4485-661 Porto, Portugal"}]}],"member":"80","reference":[{"key":"2020071615445944100_B1","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","article-title":"A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985\u20131995","volume":"83","author":"Hundahl","year":"1998","journal-title":"Cancer"},{"key":"2020071615445944100_B2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2265.2010.03898.x","article-title":"Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?","volume":"74","author":"Klubo-Gwiezdzinska","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071615445944100_B3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer","year":"2009","journal-title":"Thyroid"},{"key":"2020071615445944100_B4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1530\/eje.1.02158","article-title":"European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium","volume":"154","author":"Pacini","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071615445944100_B5","doi-asserted-by":"crossref","first-page":"v214","DOI":"10.1093\/annonc\/mdq190","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Pacini","year":"2010","journal-title":"Ann Oncol"},{"key":"2020071615445944100_B6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ncpendmet0532","article-title":"Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?","volume":"3","author":"Sherman","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2020071615445944100_B7","first-page":"988","article-title":"Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer","volume":"45","author":"Toubeau","year":"2004","journal-title":"J Nucl Med"},{"key":"2020071615445944100_B8","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jc.2004-1771","article-title":"Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma","volume":"90","author":"Kim","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2265.2006.02685.x","article-title":"Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma","volume":"66","author":"Heemstra","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071615445944100_B10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/RLU.0b013e31824852f8","article-title":"Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer","volume":"37","author":"Kendler","year":"2012","journal-title":"Clin Nucl Med"},{"key":"2020071615445944100_B11","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1210\/jc.2012-1533","article-title":"The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients","volume":"97","author":"Webb","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1210\/jc.2005-1651","article-title":"Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study","volume":"91","author":"Pacini","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1089\/thy.2012.0183","article-title":"Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence","volume":"22","author":"Hugo","year":"2012","journal-title":"Thyroid"},{"key":"2020071615445944100_B14","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","article-title":"Strategies of radioiodine ablation in patients with low-risk thyroid cancer","volume":"366","author":"Schlumberger","year":"2012","journal-title":"N Engl J Med"},{"key":"2020071615445944100_B15","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJMoa1109589","article-title":"Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer","volume":"366","author":"Mallick","year":"2012","journal-title":"N Engl J Med"},{"key":"2020071615445944100_B16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/thy.2011.0235","article-title":"Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin","volume":"22","author":"Klubo-Gwiezdzinska","year":"2012","journal-title":"Thyroid"},{"key":"2020071615445944100_B17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/thy.2009.0401","article-title":"Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"key":"2020071615445944100_B18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1210\/jc.2011-0305","article-title":"Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH","volume":"96","author":"Tala","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/105072504323150804","article-title":"Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases","volume":"14","author":"Ta\u00efeb","year":"2004","journal-title":"Thyroid"},{"key":"2020071615445944100_B20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1210\/jc.2003-031650","article-title":"Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin","volume":"89","author":"Driedger","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B21","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1210\/jc.2009-0869","article-title":"Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal","volume":"94","author":"Elisei","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/thy.2011.0242","article-title":"Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine","volume":"22","author":"Rosario","year":"2012","journal-title":"Thyroid"},{"key":"2020071615445944100_B23","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1210\/jc.2012-4137","article-title":"Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up","volume":"98","author":"Molinaro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B24","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2967\/jnumed.108.052464","article-title":"131I effective half-life and dosimetry in thyroid cancer patients","volume":"49","author":"Remy","year":"2008","journal-title":"J Nucl Med"},{"key":"2020071615445944100_B25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2006.16.177","article-title":"Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy","volume":"16","author":"Ta\u00efeb","year":"2006","journal-title":"Thyroid"},{"key":"2020071615445944100_B26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1210\/jc.2007-1404","article-title":"Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels","volume":"93","author":"Castagna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B27","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00259-005-1866-0","article-title":"Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer","volume":"32","author":"Bernier","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020071615445944100_B28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/EJE-10-0553","article-title":"Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study","volume":"163","author":"Pelttari","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2020071615445944100_B29","first-page":"855","article-title":"Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer","volume":"34","author":"Polachek","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"2020071615445944100_B30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/thy.2010.0145","article-title":"Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence","volume":"21","author":"Rosario","year":"2011","journal-title":"Thyroid"},{"key":"2020071615445944100_B31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hed.20755","article-title":"Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma","volume":"30","author":"Sawka","year":"2008","journal-title":"Head Neck"},{"key":"2020071615445944100_B32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MNM.0b013e328341c802","article-title":"Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma","volume":"32","author":"Tamilia","year":"2011","journal-title":"Nucl Med Commun"},{"key":"2020071615445944100_B33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s002590050477","article-title":"Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma","volume":"26","author":"Ronga","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"2020071615445944100_B34","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1210\/jcem.86.12.8065","article-title":"Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma","volume":"86","author":"Pacini","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2265.2008.03244.x","article-title":"Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma","volume":"69","author":"Giovanella","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071615445944100_B36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1210\/jc.2008-1931","article-title":"Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment","volume":"94","author":"Bonnet","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615445944100_B37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/000313480507100907","article-title":"The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer","volume":"71","author":"Podnos","year":"2005","journal-title":"Am Surg"},{"key":"2020071615445944100_B38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/01.sla.0000250451.59685.67","article-title":"Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone","volume":"245","author":"Roh","year":"2007","journal-title":"Ann Surg"},{"key":"2020071615445944100_B39","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s00268-007-9171-7","article-title":"Extent of routine central lymph node dissection with small papillary thyroid carcinoma","volume":"31","author":"Lee","year":"2007","journal-title":"World J Surg"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/11\/4364\/10782015\/jcem4364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/11\/4364\/10782015\/jcem4364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:01:52Z","timestamp":1715983312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/11\/4364\/2834829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-2267","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]}}}